Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soraprazan - Katairo

Drug Profile

Soraprazan - Katairo

Alternative Names: BY 359; BYK-61359; Remofuscin

Latest Information Update: 04 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ALTANA Pharma
  • Developer ALTANA Pharma; Katairo
  • Class Antiulcers; Eye disorder therapies; Imidazoles; Naphthyridines
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Stargardt disease
  • Phase I Dry age-related macular degeneration
  • Discontinued Gastro-oesophageal reflux

Most Recent Events

  • 30 May 2019 Phase-I clinical trials in Dry age-related macular degeneration in Germany (PO) (Katairo Pipeline, May 2019)
  • 09 May 2019 Phase-II clinical trials in Stargardt disease in Netherlands (PO) (EudraCT2018-001496-20)
  • 31 Oct 2007 Data presented at the 15th United European Gastroenterology Week (UEGW-2007) added to the Peptic Ulcer Disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top